ArticleCardiology journal2026
Temporal trends in the use of drug-coated balloons in Poland - an analysis based on the national registry.
Article in Cardiology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Leave-nothing-behind in calcified left main disease: expanding the boundaries of contemporary percutaneous coronary intervention.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere has been increasing interest in drug-coated balloons (DCB) within the scientific and medical community in recent years. The aim of this study was to investigate the temporal trends of DCB utilization stratified by the type of target lesion, based on a large prospective national registry.
methodsThe data for conducting the current analysis were obtained from the National Registry of Percutaneous Coronary Interventions (ORPKI, Ogólnopolski Rejestr Procedur Kardiologii Inwazyjnej), maintained in cooperation with the Association of Cardiovascular Interventions (AISN, Asocjacja Interwencji Sercowo-Naczyniowych) of the Polish Cardiac Society. The study covered data collected between January 2014 and December 2022. During this period, there were 170 active catheterization laboratories in which 899,635 percutaneous coronary intervention (PCI) procedures were performed. Among them, 5827 (0.65%) patients were treated with DCB and drug-eluting stents, 11,649 (1.29%) were treated with DCB only, and 882,159 (98.06%) were treated without DCB.
resultsThe frequency of DCB use during PCI increased across all main angiographic indications as follows: from 0.54% in 2014 to 1.02% in 2022 (p < 0.001) for de novo lesions, from 15.31% in 2014 to 33.95% in 2022 (p < 0.001) for in-stent restenosis, and from 2.41% in 2014 to 5.29% in 2022 (p < 0.001) for in-stent thrombosis. Similarly, there was a statistically significant increase in the frequency of DCB use among the following selected clinical presentations: acute heart failure (p = 0.037), cardiac arrest (p = 0.015), non-ST segment elevation myocardial infarction (p < 0.001), chronic coronary syndromes (p < 0.001), and unstable angina (p < 0.001).
conclusionsThe frequency of DCB use has been constantly increasing in recent years, regardless of angiographic indications and across different clinical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.